Larimar Therapeutics Files 8-K

Ticker: LRMR · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateMar 11, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, pharmaceutical

Related Tickers: LRMR

TL;DR

Larimar Therapeutics (LRMR) filed an 8-K on 3/11/24. No major news yet, just a standard filing.

AI Summary

Larimar Therapeutics, Inc. filed an 8-K on March 11, 2024, to report other events and financial statements. The company, formerly known as Zafgen, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. The filing does not contain specific financial figures or details about the 'other events' beyond its classification.

Why It Matters

This 8-K filing indicates that Larimar Therapeutics has made a regulatory submission, which could relate to ongoing clinical trials or business operations. Investors should monitor future filings for specific details.

Risk Assessment

Risk Level: low — This is a routine 8-K filing with no new material information provided, thus posing a low immediate risk.

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • Zafgen, Inc. (company) — Former company name
  • March 11, 2024 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

What is the primary purpose of this 8-K filing for Larimar Therapeutics?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 11, 2024.

When was Larimar Therapeutics incorporated, and in which state?

Larimar Therapeutics, Inc. was incorporated in Delaware.

What was Larimar Therapeutics' former company name?

Larimar Therapeutics, Inc.'s former company name was Zafgen, Inc.

What is the Standard Industrial Classification (SIC) code for Larimar Therapeutics?

The SIC code for Larimar Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.

What is the principal executive office address for Larimar Therapeutics?

The principal executive office address for Larimar Therapeutics is Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004.

Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-03-11 16:09:50

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

01 Other Events

Item 8.01 Other Events. Press Release On March 11, 2024, Larimar Therapeutics, Inc. (the " Company ") issued a press release announcing the dosing of the first patient in its open label extension study evaluating 25 mg daily subcutaneous injections of nomlabofusp (CTI-1601) in participants with Friedreich's ataxia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Investor Presentations On March 11, 2024, the Company posted on its website two slide presentations, which are attached as Exhibit 99.2 and 99.3 to this Current Report on Form 8-K and are incorporated herein by reference. Representatives of the Company will use these presentations in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on March 11, 2024* 99.2 Larimar Therapeutics, Inc. Corporate Presentation* 99.3 Larimar Therapeutics, Inc. Investor Presentation* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: March 11, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.